Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia

Blood

Volumn 106, Issue 4, 2005, Pages 1183-1188

  Arceci, Robert J ^a   Sande, Jane ^b   Lange, Beverly ^b   Shannon, Kevin ^b   Franklin, Janet ^b   Hutchinson, Raymond ^b   Vik, Terry A ^b   Flowers, David ^b   Aplenc, Richard ^b   Berger, Mark S ^b   Sherman, Matthew L ^b   Smith, Franklin O ^b   Bernstein, Irwin ^b   Sievers, Eric L ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; DIPHENHYDRAMINE; GEMTUZUMAB OZOGAMICIN; HYDROXYUREA; PARACETAMOL;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; BODY PAIN; BONE MARROW SUPPRESSION; CANCER REGRESSION; CANCER RELAPSE; CHEMOTHERAPY INDUCED EMESIS; CHILD; CHILDHOOD LEUKEMIA; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERBILIRUBINEMIA; HYPERHIDROSIS; HYPOKALEMIA; HYPOTENSION; IRON DEFICIENCY ANEMIA; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MULTIDRUG RESISTANCE; NAUSEA; NECK PAIN; PAIN; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROTEIN DETERMINATION; SEPSIS; SWEATING; TACHYCARDIA; THROMBOCYTOPENIA; VEIN OCCLUSION;

EID: 23744511263     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-10-3821     Document Type: Article

References (29)

1. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2001. Vol 2005. Bethesda, MD: National Cancer Institute; 2004.
2. Xie Y, Davies SM, Xiang Y, Robison LL, Ross JA. Trends in leukemia incidence and survival in the United States (1973-1998). Cancer. 2003;97:2229-2235.
3. Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood. 2001;97:56-62.
4. Creutzig U, Ritter J, Zimmermann M, et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol. 2001;19:2705-2713.
5. Loeb DM, Bowers DC, Civin CI, Friedman AD. Intensive timed sequential remission induction chemotherapy with high-dose cytarabine for childhood acute myeloid leukemia. Med Pediatr Oncol. 2001;37:365-371.
6. Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial: MRC Childhood Leukaemia Working Party. Br J Haematol. 1998;101:130-140.
7. Webb DK, Harrison G, Stevens RF, Gibson BG, Hann IM, Wheatley K. Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood. 2001;98:1714-1720.
8. Loeb DM, Arceci RJ. What is the optimal therapy for childhood AML? Oncology (Huntingt). 2002;16:1057-1066;discussion 1066, 1068-1070.
9. Hamann PR, Hinman LM, Hollander I, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem. 2002;13:47-58.
10. Dinndorf PA, Andrews RG, Benjamin D, Ridgway D, Wolff L, Bernstein ID. Expression of normal myeloid-associated antigens by acute leukemia cells. Blood. 1986;67:1048-1053.
11. Ikemoto N, Kumar RA, Ling TT, Ellestad GA, Danishefsky SJ, Patel DJ. Calicheamicin-DNA complexes: warhead alignment and saccharide recognition of the minor groove. Proc Natl Acad Sci USA. 1995;92:10506-10510.
12. Mylotarg [package insert], Philadelphia, PA: Wyeth Pharmaceuticals, Inc; 2004.
13. Berger MS, Leopold LH, Dowell JA, Korth-Bradley JM, Sherman ML. Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse. Invest New Drugs. 2002;20:395-406.
14. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7:1490-1496.
15. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19:3244-3254.
16. Larson RA, Boogaerts M, Estey E, et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia. 2002;16:1627-1636.
17. Sievers EL, Arceci RJ, Franklin J. Preliminary report of an ascending dose study of gemtuzumab ozogamicin (Mylotarg™, CMA-676) in pediatric patients with acute myeloid leukemia [abstract]. Blood. 2000;96:217b. Abstract 4663.
18. Zwaan CM, Reinhardt D, Corbacioglu S, et al. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood. 2003;101:3868-3871.
19. Reinhardt D, Diekamp S, Fleischhack G, et al. Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia. Ontologic. 2004;27:269-272.
20. Buckwalter M, Dowell JA, Korth-Bradley J, Gorovits B, Mayer PR. Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Pharmacol. 2004;44:873-880.
21. McDonald GB, Hinds MS, Fisher LD, et al. Venoocclusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118:255-267.
22. Linenberger ML, Hong T, Flowers D, et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood. 2001;98:988-994.
23. Larson RA, Sievers EL, Stadtmauer EA, et al. A final analysis of the efficacy and safety of gemtuzumab ozogamicin in 277 patients with acute myeloid leukemia in first relapse [abstract]. Blood. 2002:338a.
24. Erba HP, Stadtmauer EA, Larson RA. Risk assessment for hepatic veno-occlusive disease in patients treated with gemtuzumab ozogamicin (Mylotarg) with or without hematopoietic stem cell transplantation [abstract]. Blood. 2003;102. Abstract 3241.
25. Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003;102:1578-1582.
26. Sievers EL, Smith FO, Woods WG, et al. Cell surface expression of the multidrug resistance P-glycoprotein (P-170) as detected by monoclonal antibody MRK-16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: a report from the Children's Cancer Group. Leukemia. 1995;9:2042-2048.
27. den Boer ML, Pieters R, Kazemier KM, et al. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood. 1998;91:2092-2098.
28. De Angelo DJ, Stone RM, Durrant S, et al. Gemtuzumab ozogamicin (Mylotarg) in combination with induction chemotherapy for the treatment of patients with de novo acute myeloid leukemia: two age-specific phase 2 trials [abstract]. Blood. 2003;102. Abstract 341.
29. Bhattacharyya R, Versluys B, Steward C, Oakhill A, Cornish J, Goulden N. Gemtuzumab ozogamicin followed by SCT in children with refractory AML; low incidence of VOD [abstract]. Blood. 2003;102. Abstract 2605.